Search

Your search keyword '"Blanca-López, Natalia"' showing total 40 results
Start Over Author "Blanca-López, Natalia" Publisher elsevier b.v.
40 results on '"Blanca-López, Natalia"'

1. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.

Author

Muñoz-Gómez, María José, Ryan, Pablo, Quero-Delgado, Marta, Martin-Vicente, María, Cuevas, Guillermo, Valencia, Jorge, Jiménez, Eva, Blanca-López, Natalia, Lara-Álvarez, Miguel Ángel, Hernández-Rivas, José Ángel, Redondo, Gerardo, Mas, Vicente, Sepúlveda-Crespo, Daniel, Vázquez, Mónica, Torres-Macho, Juan, Martínez, Isidoro, and Resino, Salvador

Abstract

Cancer patients often have weakened immune systems, resulting in a lower response to vaccines, especially those receiving immunosuppressive oncological treatment (OT). We aimed to assess the impact of OT on the humoral and T-cell response to the B.1 lineage and Omicron variant following COVID-19 vaccination in patients with solid and hematological neoplasms. We conducted a prospective study on cancer patients, stratified into OT and non-OT groups, who received a two-dose series of the COVID-19 mRNA vaccine and a booster six months later. The outcomes measured were the humoral (anti-SARS-CoV-2 S IgG titers and ACE2-S interaction inhibition capacity) and cellular (SARS-CoV-2 S-specific T-cell spots per million PBMCs) responses against the B.1 lineage and Omicron variant. These responses were evaluated four weeks after the second dose (n = 98) and eight weeks after the booster dose (n = 71). The humoral response after the second vaccine dose against the B.1 lineage and Omicron variant was significantly weaker in the OT group compared to the non-OT group (q-value<0.05). A booster dose of the mRNA-1273 vaccine significantly improved the humoral response in the OT group, making it comparable to the non-OT group. The mRNA-1273 vaccine, designed for the original Wuhan strain, elicited a weaker humoral response against the Omicron variant compared to the B.1 lineage, regardless of oncological treatment or vaccine dose. In contrast, T-cell responses against SARS-CoV-2, including the Omicron variant, were already present after the second vaccine dose and were not significantly affected by oncological treatments. Cancer patients, particularly those receiving immunosuppressive oncological treatments, should require booster doses and adapted COVID-19 vaccines for new SARS-CoV-2 variants like Omicron. Future studies should evaluate the durability of the immune response and the efficacy of individualized regimens. [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Anaphylaxis in Hypersensitivity reactions to NSAIDs.

Author

Prieto-Moreno Pfeifer, Ana María, Pérez-Alzate, Diana, Rojas, Isabel Torres, Somoza Álvarez, Maria Luisa, Haroun-Díaz, Elisa, Vázquez de la Torre, Maria, López-Gonzalez, Paula, Cervera Garcia, Maria Desamparados, Blanco-Mota, Carlos, Vera, Elena Diaz, Ruano, Francisco, and Blanca-López, Natalia

Published
2022
Full Text
View/download PDF

7. Beta-lactam-induced immediate hypersensitivity reactions: A genome-wide association study of a deeply phenotyped cohort.

Author

Nicoletti, Paola, Carr, Daniel F., Barrett, Sarah, McEvoy, Laurence, Friedmann, Peter S., Shear, Neil H., Nelson, Matthew R., Chiriac, Anca M., Blanca-López, Natalia, Cornejo-García, José A., Gaeta, Francesco, Nakonechna, Alla, Torres, Maria J., Caruso, Cristiano, Valluzzi, Rocco L., Floratos, Aris, Shen, Yufeng, Pavlos, Rebecca K., Phillips, Elizabeth J., and Demoly, Pascal

Abstract

β-lactam antibiotics are associated with a variety of immune-mediated or hypersensitivity reactions, including immediate (type I) reactions mediated by antigen-specific IgE. We sought to identify genetic predisposing factors for immediate reactions to β-lactam antibiotics. Patients with a clinical history of immediate hypersensitivity reactions to either penicillins or cephalosporins, which were immunologically confirmed, were recruited from allergy clinics. A genome-wide association study was conducted on 662 patients (the discovery cohort) with a diagnosis of immediate hypersensitivity and the main finding was replicated in a cohort of 98 Spanish cases, recruited using the same diagnostic criteria as the discovery cohort. Genome-wide association study identified rs71542416 within the Class II HLA region as the top hit (P = 2 × 10−14); this was in linkage disequilibrium with HLA-DRB1∗10:01 (odds ratio, 2.93; P = 5.4 × 10−7) and HLA-DQA1∗01:05 (odds ratio, 2.93, P = 5.4 × 10−7). Haplotype analysis identified that HLA-DRB1∗10:01 was a risk factor even without the HLA-DQA1∗01:05 allele. The association with HLA-DRB1∗10:01 was replicated in another cohort, with the meta-analysis of the discovery and replication cohorts showing that HLA-DRB1∗10:01 increased the risk of immediate hypersensitivity at a genome-wide level (odds ratio, 2.96; P = 4.1 × 10−9). No association with HLA-DRB1∗10:01 was identified in 268 patients with delayed hypersensitivity reactions to β-lactams. HLA-DRB1∗10:01 predisposed to immediate hypersensitivity reactions to penicillins. Further work to identify other predisposing HLA and non-HLA loci is required. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

20. Allergy to Heparins.

Author

Ruano Pérez, Francisco Javier, Alzate, Diana Perez, Blanca-López, Natalia, Somoza, Maria Luisa, De La Torre, Maria Vazquez, Garcimartin, Maria Isabel, Haroun, Elisa, and Canto, Gabriela

Published
2016
Full Text
View/download PDF

22. HLA-DRA variants predict penicillin allergy in genome-wide fine-mapping genotyping.

Author

Guéant, Jean-Louis, Romano, Antonino, Cornejo-Garcia, Jose-Antonio, Oussalah, Abderrahim, Chery, Celine, Blanca-López, Natalia, Guéant-Rodriguez, Rosa-Maria, Gaeta, Francesco, Rouyer, Pierre, Josse, Thomas, Canto, Gabriella, Carmona, F. David, Bossini-Castillo, Lara, Martin, Javier, Laguna, Jose-Julio, Fernandez, Javier, Feo, Francisco, Ostrov, David A., Plasencia, Pablo C., and Mayorga, Cristobalina

Abstract

Background Immediate reactions to β-lactams are the most common causes of anaphylactic reactions and can be life-threatening. The few known genetic factors influencing these reactions suggest a link with atopy and inflammation. Objective We performed a fine-mapping genome-wide association study of the genetic predictors of β-lactam allergy to better understand the underlying mechanisms. Methods We studied 387 patients with immediate allergic reactions to β-lactams and 1124 paired control subjects from Spain. We replicated the results in 299 patients and 362 paired control subjects from Italy. Results We found significant associations with the single nucleotide polymorphisms rs4958427 of ZNF300 (c.64-471G>A, P = 9.9 × 10 −9 ), rs17612 of C5 (c.4311A>C [p.Glu1437Asp], P = 7.5 × 10 −7 ), rs7754768 and rs9268832 of the HLA-DRA | HLA-DRB5 interregion ( P = 1.6 × 10 −6 and 4.9 × 10 −6 ), and rs7192 of HLA-DRA (c.724T>G [p.Leu242Val], P = 7.4 × 10 −6 ) in an allelic model, with similar results in an additive model. Single nucleotide polymorphisms of HLA-DRA and ZNF300 predicted skin test positivity to amoxicillin and other penicillins but not to cephalosporins. A haplotype block in HLA-DRA and the HLA-DRA | HLA-DRB5 interregion encompassed a motif involved in balanced expression of the α- and β-chains of MHC class II, whereas rs7192 was predicted to influence α-chain conformation. HLA-DRA rs7192 and rs8084 were significantly associated with allergy to penicillins and amoxicillin ( P = 6.0 × 10 −4 and P = 4.0 × 10 −4 , respectively) but not to cephalosporins in the replication study. Conclusions Gene variants of HLA-DRA and the HLA-DRA | HLA-DRB5 interregion were significant predictors of allergy to penicillins but not to cephalosporins. These data suggest complex gene-environment interactions in which genetic susceptibility of HLA type 2 antigen presentation plays a central role. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

30. A Genome-Wide Association Study of Non-Steroidal Antiinflammatory Drugs (NSAIDs)-Induced Acute Urticaria in the Spanish Population.

Author

Lee, Mike T.M., Cornejo-Garcia, Jose A., Chen, Yuan-Tsong, Chen, Chien-Hsiun, Blanca-López, Natalia, Doña, Inmaculada, Torres, Maria J., Rondon, Carmen, Campo, Paloma, Laguna, Jose Julio, Fernandez, F. Javier, Parejo, Pedro Ayuso, Plaza-Serón, Maria del Carmen, Gandolfo Cano, Maria Del Mar, Ingelmo, Ana Rosado, Canto, Gabriela, and Blanca, Miguel

Published
2013
Full Text
View/download PDF

31. Association Study of Functional Polymorphisms in Genes Involved in Histamine Homeostasis and Multiple NSAID–Triggered Urticaria and/or Angioedema and Anaphylaxis in Patients without Pre-Existing Chronic Urticaria (MNSAID-UA).

Author

Parejo, Pedro Ayuso, García-Agúndez, Jose Augusto, Cornejo-Garcia, Jose A., Blanca, Miguel, Torres, María José, Doña, Inmaculada, Salas, Maria, Blanca-López, Natalia, Canto, Gabriela, Rondon, Carmen, Campo, Paloma, Laguna, Jose Julio, Fernandez, F. Javier, Martínez, Carmen, and García-Martín, Elena

Published
2013
Full Text
View/download PDF

38. T-cell involvement in delayed-type hypersensitivity reactions to infliximab.

Author

Torres, Maria Jose, Chaves, Patrícia, Doña, Inmaculada, Blanca-López, Natalia, Canto, Gabriela, Mayorga, Cristobalina, and Blanca, Miguel

Subjects
DRUG allergy, INFLIXIMAB
Abstract

A letter to the editor is presented in response to the article "T-cell involvement in delayed-type hypersensitivity reactions to infliximab" by Maria Jose Torres and colleagues in the 2011 issue.

Published
2011
Full Text
View/download PDF

40. Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole.

Author

Martínez, Carmen, Andreu, Inmaculada, Amo, Gemma, Miranda, Miguel A., Esguevillas, Gara, Torres, María José, Blanca-López, Natalia, Blanca, Miguel, García-Martín, Elena, and Agúndez, José A.G.

Subjects
*BIOTRANSFORMATION (Metabolism), *GENETIC polymorphisms, *ANALGESICS, *ANTISPASMODICS, *DRUG carriers, *DRUG side effects, *BIOMARKERS, *THERAPEUTICS
Abstract

Metamizole is a pain-killer drug that has been banned in some countries because of its toxicity, but it is still used in many countries due to its effective analgesic and antispasmodic properties. Although large variability in the biodisposition and adverse effects of metamizole are known, factors underlying this variability are poorly understood. We analyzed the urinary recovery of metabolites, as well as the association of these profiles with genetic and non-genetic factors, in a group of 362 healthy individuals. Gender and functional polymorphisms are strongly related to metabolic profiles. N -demethylation of the active metabolite MAA is diminished in carriers of the CYP2C19*2 allele and in NAT2 -slow acetylators. Acetylation of the secondary metabolite AA is decreased in men, in drinkers and in NAT2-slow acetylators with a differential effect of NAT2*5 and NAT2*6 alleles. The formylation of MAA is diminished in older subjects and in carriers of defect CYP2C9 and CYP2C19 alleles. Two novel arachidonoyl metabolites were identified for the first time in humans. Women and NAT2-slow acetylators show higher concentrations, whereas the presence of the rapid CYP2C19*17 allele is associated with lower concentrations of these metabolites. All genetic associations show a gene-dose effect. We identified for the first time genetic and non-genetic factors related to the oxidative metabolism of analgesic drug metamizole, as well as new active metabolites in humans. The phenotypic and genetic factors identified in this study have a potential application as biomarkers of metamizole biotransformation and toxicity. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results